A new drug for adhesion dermatitis (AD) ! AbbVie oral JAK inhibitor Rinvoq single drug treatment of severe AD Phase II PHASE III STUDY WAS SUCCESSFUL!

AbbVie () recently announced that the evaluation of oral inhibitors () single drug therapy for aspecific dermatitis () phase II clinical study ( ) has reached the primary and all secondary endpointsThe study, conducted in moderate to severe adolescent and adult patients, showed that the common primary endpoint was reached in the first week of treatment (and once a day): the eczema area and severity index improved at least (), and the overall assessment () of the validated epidermal dermatitis researchers was scored as complete or almost completely cleared of skin damage ()In addition, the dose also effectively and rapidly reduced itching compared to placebo dose one day after the first administration (day), the dose two days after the first administration (day) showed a clinical improvement in itchingIt is the second critical study to evaluate the treatment of moderate-severe adhesitisPatients treated with milligrams or milligrams of monodrug in this study showed significant improvement in skin loss removalThe specific data are: () in the first week of treatment group and group, respectively, the patients reached and the placebo group is ()() In the first week of treatment, the patients in the group and the group respectively achieved a score for the placebo group ()In addition, patients with additional doses experienced early relief of itching until the first weekClinically itching relief is defined as the most severe itching numerical lysage () improvementThe data showed a significant increase in the proportion of patients in the first week of treatment and in the group who achieved clinically significant increasein itching improvement in the group compared to the placebo group (: , , , respectivelyOf particular concern was the clinically significant reduction in itching observed by the group on the day after the first administration (the first day), two days after the first administration (the day) compared to the placebo group (group placebo group; placebo group)No new safety risks were observed in the treatment of aditour dermatitis () compared to the safety observed in patients with rheumatoid arthritis () and psoriasis ()The full results of the study will be presented at a future medical conference and in the peer-reviewed journalAdhematitis () is a common, chronic, recurrent, inflammatory skin disease manifested as itching and scratching of repeated circulation leading to skin pain, ruptureIt is estimated that as many teenagers and adults will be affected at some point in their livesAdult patients will have moderate to severe illnessThe symptoms of the disease can place a significant physical, psychological and economic burden on the patient "Patients with terioderitis often struggle with relentless skin symptoms and persistent itching symptoms that lead to severely unmet medical needs," said Mr M.D., AbbVie's Vice President and President We are encouraged by these results, which confirm the data from the study and highlight the therapeutic potential for patients with atopic dermatitis Lead investigator, Professor of Dermatology at Trinity College Dublin, Ireland, said: "Special dermatitis is more than just a rash or itching of the skin Many patients with moderate to severe symptoms continue to suffer severe physical and mental burdens These data support our continued efforts to provide more options for patients with moderate to severe adhesion dermatitis "The active drug ingredient is an oral selective and reversible inhibitor that is being discovered and developed by AbbVie and is being developed to treat several immuno-mediated inflammatory diseases It is a kinase that plays a key role in the pathophysiological process of a variety of inflammatory diseases In the United States, it was the world's first adult patient to be treated for the treatment of moderate to severe active rheumatoid arthritis () with insufficient response to methotrexate () or intolerance Obtained EU approval for the treatment of moderate to severe adult patients with inadequate response or intolerance of anti-rheumatic drugs () for one or more diseases The approved dose in is Currentclinical clinical studies are under way to treat psoriasis arthritis (), mid-axis spinal arthritis (), Crohn's disease (), epigenetic dermatitis (), ulcerative colitis (), cytomegaloblastitis () It was recently announced that AbbVie had filed a (once a daily) application for new indications in the United States and the European Union to treat active adult patients The industry is very optimistic about the business prospects A previous report by the pharmaceutical market research firm predicted that global sales would reach US$100 million in the year, making it the world's top-selling anti-rheutic drug () Origins: